Cargando…

Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis

Differentiating viral from bacterial infections in febrile children is challenging and often leads to an unnecessary use of antibiotics. There is a great need for more accurate diagnostic tools. New molecular methods have improved the particular diagnostics of viral respiratory tract infections, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhedin, Samuel, Elfving, Kristina, Berggren, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623137/
https://www.ncbi.nlm.nih.gov/pubmed/34828783
http://dx.doi.org/10.3390/children8111070
_version_ 1784605859373907968
author Rhedin, Samuel
Elfving, Kristina
Berggren, Anna
author_facet Rhedin, Samuel
Elfving, Kristina
Berggren, Anna
author_sort Rhedin, Samuel
collection PubMed
description Differentiating viral from bacterial infections in febrile children is challenging and often leads to an unnecessary use of antibiotics. There is a great need for more accurate diagnostic tools. New molecular methods have improved the particular diagnostics of viral respiratory tract infections, but defining etiology can still be challenging, as certain viruses are frequently detected in asymptomatic children. For the detection of bacterial infections, time consuming cultures with limited sensitivity are still the gold standard. As a response to infection, the immune system elicits a cascade of events, which aims to eliminate the invading pathogen. Recent studies have focused on these host–pathogen interactions to identify pathogen-specific biomarkers (gene expression profiles), or “pathogen signatures”, as potential future diagnostic tools. Other studies have assessed combinations of traditional bacterial and viral biomarkers (C-reactive protein, interleukins, myxovirus resistance protein A, procalcitonin, tumor necrosis factor-related apoptosis-inducing ligand) to establish etiology. In this review we discuss the performance of such novel diagnostics and their potential role in clinical praxis. In conclusion, there are several promising novel biomarkers in the pipeline, but well-designed randomized controlled trials are needed to evaluate the safety of using these novel biomarkers to guide clinical decisions.
format Online
Article
Text
id pubmed-8623137
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86231372021-11-27 Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis Rhedin, Samuel Elfving, Kristina Berggren, Anna Children (Basel) Review Differentiating viral from bacterial infections in febrile children is challenging and often leads to an unnecessary use of antibiotics. There is a great need for more accurate diagnostic tools. New molecular methods have improved the particular diagnostics of viral respiratory tract infections, but defining etiology can still be challenging, as certain viruses are frequently detected in asymptomatic children. For the detection of bacterial infections, time consuming cultures with limited sensitivity are still the gold standard. As a response to infection, the immune system elicits a cascade of events, which aims to eliminate the invading pathogen. Recent studies have focused on these host–pathogen interactions to identify pathogen-specific biomarkers (gene expression profiles), or “pathogen signatures”, as potential future diagnostic tools. Other studies have assessed combinations of traditional bacterial and viral biomarkers (C-reactive protein, interleukins, myxovirus resistance protein A, procalcitonin, tumor necrosis factor-related apoptosis-inducing ligand) to establish etiology. In this review we discuss the performance of such novel diagnostics and their potential role in clinical praxis. In conclusion, there are several promising novel biomarkers in the pipeline, but well-designed randomized controlled trials are needed to evaluate the safety of using these novel biomarkers to guide clinical decisions. MDPI 2021-11-20 /pmc/articles/PMC8623137/ /pubmed/34828783 http://dx.doi.org/10.3390/children8111070 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rhedin, Samuel
Elfving, Kristina
Berggren, Anna
Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis
title Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis
title_full Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis
title_fullStr Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis
title_full_unstemmed Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis
title_short Novel Biomarkers Differentiating Viral from Bacterial Infection in Febrile Children: Future Perspectives for Management in Clinical Praxis
title_sort novel biomarkers differentiating viral from bacterial infection in febrile children: future perspectives for management in clinical praxis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623137/
https://www.ncbi.nlm.nih.gov/pubmed/34828783
http://dx.doi.org/10.3390/children8111070
work_keys_str_mv AT rhedinsamuel novelbiomarkersdifferentiatingviralfrombacterialinfectioninfebrilechildrenfutureperspectivesformanagementinclinicalpraxis
AT elfvingkristina novelbiomarkersdifferentiatingviralfrombacterialinfectioninfebrilechildrenfutureperspectivesformanagementinclinicalpraxis
AT berggrenanna novelbiomarkersdifferentiatingviralfrombacterialinfectioninfebrilechildrenfutureperspectivesformanagementinclinicalpraxis